Eledon Pharmaceuticals (NASDAQ:ELDN) Stock Rating Upgraded by Wall Street Zen

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

ELDN has been the topic of several other reports. Rodman & Renshaw started coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, July 21st. They issued a “buy” rating and a $12.00 price target on the stock. Weiss Ratings raised shares of Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, November 9th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.00.

Get Our Latest Stock Analysis on Eledon Pharmaceuticals

Eledon Pharmaceuticals Price Performance

Shares of ELDN stock opened at $2.12 on Friday. The company’s fifty day simple moving average is $2.56 and its 200-day simple moving average is $3.11. The firm has a market cap of $172.27 million, a PE ratio of -2.90 and a beta of 0.95. Eledon Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $4.49.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.01. On average, equities analysts predict that Eledon Pharmaceuticals will post -0.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc bought a new stake in Eledon Pharmaceuticals during the second quarter worth $28,000. Grandfield & Dodd LLC acquired a new stake in Eledon Pharmaceuticals in the second quarter valued at $39,000. Daytona Street Capital LLC grew its position in shares of Eledon Pharmaceuticals by 12.9% in the 3rd quarter. Daytona Street Capital LLC now owns 91,666 shares of the company’s stock valued at $231,000 after acquiring an additional 10,500 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of Eledon Pharmaceuticals in the 2nd quarter valued at about $43,000. Finally, Bank of New York Mellon Corp grew its position in shares of Eledon Pharmaceuticals by 8.5% in the 1st quarter. Bank of New York Mellon Corp now owns 144,148 shares of the company’s stock valued at $444,000 after acquiring an additional 11,246 shares during the period. Institutional investors and hedge funds own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

(Get Free Report)

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS.

Further Reading

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.